Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perampanel - Eisai

Next Previous
X
Search
Drug Profile

Perampanel - Eisai

Alternative Names: E-2007; ER-155055-90; FYCOMPA; Fycompa

Latest Information Update: 28 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ESTEVE
  • Class Analgesics; Antiepileptic drugs; Nitriles; Pyridines; Pyridones; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies; Tonic-clonic epilepsy
  • Registered Epilepsy
  • Phase III Seizures
  • Discontinued Migraine; Multiple sclerosis; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 31 Jan 2024 Registered for Epilepsy in Japan (IV), before January 2024
  • 16 May 2023 Eisai completes a phase I/II trial in Seizures (Prevention) in USA (PO, Tablet) (NCT04497142)
  • 25 Apr 2023 Eisai completes a phase II trial in Epilepsy (Adjunctive treatment, In children, In infants) in Latvia, USA (PO) (EudraCT2013-005391-17) (NCT02914314)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top